The Latest Breaking News from NeoGenomics

NeoGenomics CEO Mark Mallon stepped down Tuesday and the company expects light first-quarter results, leading NEO stock to tank.

Upgrades

NeoGenomics Inc's (NASDAQ:NEO) CEO Mark Mallon will step down as CEO and member of the Board, effective immediately.  The Board has retained Russell Reynolds to search for the Company's next CEO The Board has appointed current Chair Lynn Tetrault, Esq. as Executive Chair and established an Interim Office of the CEO.  Read…

BTIG cut the price target on NeoGenomics, Inc. (NASDAQ: NEO) from $35 to $28. NeoGenomics shares fell 29.2% to $12.60 in pre-market trading.

Over the past 3 months, 8 analysts have published their opinion on NeoGenomics (NASDAQ:NEO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Here's a roundup of top developments in the biotech space over the last 24 hours:

NeoGenomics (NASDAQ:NEO) brought in sales totaling $125.73 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 105.22%, resulting in a loss of $41.76 million.

  NeoGenomics (NASDAQ:NEO) reported its Q4 earnings results on Wednesday, February 23, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings NeoGenomics reported in-line EPS of $-0.14 versus an estimate of $-0.14.